Hyderabad: NATCO Pharma Limited has recorded consolidated total revenue of INR 2078.9 Crore for the year ended on 31 st March, 2017, as against INR 1089.7 Crore for the last year, reflecting an year-overyear growth of 90.8%.
The net profit for the period, on a consolidated basis, was INR 486.0 Crore, as against INR 157.1 Crore last year, showing a growth of 209.3%.
For the fourth quarter (Q4) ended March 31st, 2017, the company recorded a net revenue of INR 577.2 Crore, on a consolidated basis, as against INR 394.8 Crore during Q4, FY 2016, posting an increase of 46.2%.
The profit after tax, on a consolidated basis, was recorded as INR 176.7 Crore for the quarter, as against INR 62.8 Crore same quarter last year, showing a growth of 181.4%.
The revenue and profit growth for the company during the financial year was driven primarily due to the sales of generic Oseltamivir product in the USA market and continued growth of domestic formulations business.
All results for the quarter and previous year FY2016 have been restated to comply with Indian Accounting Standards (Ind AS) to make them comparable.